4 completed, 1 recruiting, 1 terminated, 1 unknown. 7 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Attention Deficit Hyperactivity Disorder (ADHD): new trials by email Literature Review of Attention Deficit Hyperactivity Disorder (ADHD) trials Research Report on Attention Deficit Hyperactivity Disorder (ADHD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 630 | 2025-04-30 | 2026-10-23 |
| The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD Oral CBD oil enriched with terpenes, Oral Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Unknown | Bazelet Nehushtan LtD. | 120 | 2024-08-22 | 2024-08-23 |
| Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task - Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression | Phase 2 | Terminated | Supernus Pharmaceuticals, Inc. | 7 | 2019-05-30 | 2025-05-02 |
| Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder SPD489 - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Completed | Shire | 24 | 2015-04-15 | 2021-06-08 |
| Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits ADHD Medication, Omega-3 Fatty Acids - Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR) | Phase 2 | Completed | Massachusetts General Hospital | 2 | 2012-02-01 | 2018-10-23 |
| Classroom-based Distance Intervention for Teachers of Children With Attention Deficit Hyperactivity Disorder Teacher Help for ADHD - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Completed | Dalhousie University | 116 | 2012-02-01 | 2014-03-28 |
| Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Neurofeedback, Exercise, methylphenidate - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Completed | R. van Mourik | 112 | 2010-06-01 | 2015-12-09 |
Attention Deficit Disorder with Hyperactivity (7) · Motor Activity (1) · Spasm (1)
Attention Deficit and Disruptive Behavior Disorders (7) · Mental Disorders (7) · Neurodevelopmental Disorders (7) · Behavior (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Methylphenidate (2) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (1) · Adderall (1) · Amphetamine (1) · Atomoxetine Hydrochloride (1) · Biofeedback, Psychology (1) · Dexmethylphenidate Hydrochloride (1) · Dextroamphetamine (1) · Exercise (1) · Fatty Acids, Omega-3 (1) · Lisdexamfetamine Dimesylate (1) · Magnetic Resonance Imaging (1) · Neurofeedback (1) · Positron-Emission Tomography (1) · Saposins (1)
Bazelet Nehushtan LtD. (1) · Dalhousie University (1) · Massachusetts General Hospital (1) · Otsuka Pharmaceutical Co., Ltd. (1) · R. van Mourik (1) · Shire (1) · Supernus Pharmaceuticals, Inc. (1)
United States (3) · Canada (1) · Israel (1) · Japan (1) · Netherlands (1)
Craig Surman, MD (1) · Jaap Oosterlaan, Professor (1) · Matitiahu Berkovitch, MD (1) · Nezihe Elik, PhD (1) · Nobuhito Sanada (1) · Penny V Corkum, PhD (1) · Rosa van Mourik, PhD (1)
PMID 26748531, PMID 26771913, PMID 27631143, PMID 27866283, PMID 29098467, PMID 32233956, PMID 32304847